CYTOKINETICS INC 4

President & CEO Robert I. Blum of Cytokinetics Inc. exercised 7,500 stock options at $10.60 and sold 7,500 shares of common stock at $80.87 on 2026-07-27, leaving 377,820 shares owned directly and 4,166 shares held indirectly through trusts.

On July 27, 2026, Cytokinetics Inc. President & CEO Robert I. Blum exercised a non-qualified stock option for 7,500 shares of common stock at an exercise price of $10.60 per share and immediately sold the same 7,500 shares at an average price of $80.87 per share in a same‑day transaction. The option exercise added 7,500 shares to his direct holdings, which were then reduced by the sale back to a net decrease of 7,500 shares from what would otherwise have been held, leaving him with 377,820 shares owned directly after the transaction. He also indirectly beneficially owns 2,083 shares of common stock in each of two irrevocable trusts (The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust), for a total of 4,166 indirectly held shares. Based on the reported sale price as a proxy for current market value, Mr. Blum’s direct holdings after the transaction are worth approximately $30.5 million, and his indirect trust holdings are worth roughly $0.3 million, indicating that this was a sizable but not portfolio‑threatening liquidity event tied to option-related compensation.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000085

Alert Tier

6